The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.
about
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyGemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaA three-signal model of T-cell lymphoma pathogenesisChallenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma.A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.MicroRNA profiling in peripheral T-cell lymphoma, not otherwise specified.Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphomaComparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma
P2860
Q33429898-5501DB80-B516-4656-AB30-669A738AD6A0Q33434137-C0F233E5-98F4-4055-822D-5780691844C2Q33436867-2C14F88F-9497-4BF5-8888-0F03FED91723Q33702340-DB577B66-5FD6-4875-AA31-2BA3E5D6AAF9Q35859219-0EADA4AA-3FE6-41D2-BA6E-DBB4EA2C74D5Q36384484-B623B36E-2617-4A1D-AA61-17EA97BCEFF1Q38593164-A481774C-204F-4F83-AFD4-D6FB455162C7Q39055861-AFEFAA2E-5CA9-4787-B9F9-C0B1E53ED2C6Q40444551-985F1B94-F5CE-4B79-BDDD-25D3F69E316CQ40476069-9D922509-A05F-4BE4-91CA-F8D46838ABBCQ47097471-AFE3A3E0-D00A-4532-9DC6-C6EAF1BC8D0DQ47902760-3F513702-A847-43F2-B56B-382C6B628E87Q52782304-135C853B-ADE9-4391-9D4F-08BA88277350Q52919265-E8352337-EF9F-489A-BA06-0B7C2DCD7DA0Q58690869-A21B0C4A-5578-4848-832A-1BDC65CE502CQ58705889-C6F8DEAB-572C-43F7-81C4-2307F73CA39B
P2860
The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@ast
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@en
type
label
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@ast
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@en
prefLabel
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@ast
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@en
P2093
P2860
P50
P356
P1433
P1476
The role of front-line anthrac ...... n peripheral T-cell lymphomas.
@en
P2093
D J Inwards
G S Nowakowski
J P Colgan
M S Kaminski
R A Wilcox
S M Ansell
T E Witzig
T M Habermann
P2860
P2888
P356
10.1038/BCJ.2014.34
P577
2014-05-30T00:00:00Z
P5875
P6179
1016999790